Topic:

Chutes and Ladders

Latest Headlines

Latest Headlines

UPDATED: Merck's new R&D chief Perlmutter begins major shakeup

Twitter lit up Friday after one of Derek Lowe's posts on his In the Pipeline blog elicited an anonymous but very specific comment on changes being made in R&D now that Roger Perlmutter has taken over the research division.

Icahn ally added to Forest board

Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Michael Gibney (email | Twitter) or Emily Mullin (email |...

Top AstraZeneca exec bows out to helm a biotech

AstraZeneca's announcement early this year that Peter Greenleaf would be "promoted" from the head of MedImmune to the top job in the company's big Latin American division raised a few eyebrows around the industry.

Forest, Icahn playing nice this time around

In a stark turnabout from last year, Forest Laboratories and cantankerous investor Carl Icahn are making nice ahead of the company's annual shareholder meeting.

Forest prepares to negotiate with investor Icahn on board positions

Forest Laboratories faces another proxy battle as its annual investor meeting this summer looms. Icahn, the company's second largest shareholder, has been highly critical of the company's leadership.

Forrester is Verastem CEO after Westphal steps down

Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Michael Gibney (email | Twitter) or Emily Mullin (email |...

Reuters: Forest, Icahn negotiate to avoid 3rd proxy battle

For two summers, a fight between Forest Laboratories and Carl Icahn provided the industry with plenty of drama as the activist investor fought to install a slate of allies on the drugmaker's board. The deadline is again looming to nominate alternative directors, but there is a chance Forest may be able to appease Icahn enough to prevent a third public brawl.

UPDATED: Aveo slashes 140 jobs, halts R&D work related to doomed FDA drug application

Staring straight at an almost certain FDA rejection for its kidney cancer drug tivozanib, Cambridge, MA-based Aveo Oncology today grabbed the budget ax and hacked deep into its staff. A total of 140 workers are being laid off--62% of its workforce--and the biotech's COO is joining the exodus in July.

Achillion CEO retires, Chief Scientific Officer Deshpande to step into role

Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Michael Gibney (email | Twitter) or Emily Mullin (email |...

Pharmaxis slashes staff after FDA red-flags cystic fibrosis treatment

The biotech says it will cut 48 jobs, or about a third of its workforce, as it gets ready to try to satisfy regulators with another study of the therapy, which is marketed in Europe.